Informations générales (source: ClinicalTrials.gov)
Study on the Occurrence of Head and Neck Cancers During Pregnancy
Observational
Centre Francois Baclesse (Voir sur ClinicalTrials)
novembre 2018
septembre 2025
02 octobre 2025
Head and neck cancers that occurred during pregnancy
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Ingrid BREUSKIN | 17/02/2024 12:26:19 | Contacter | ||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Chu Besancon - Besançon 3033123 - France | Contact (sur clinicalTrials) | ||||
| Chu Bordeaux - Bordeaux 3031582 - France | Contact (sur clinicalTrials) | ||||
| Chu Grenoble Alpes - Grenoble 3014728 - France | Contact (sur clinicalTrials) | ||||
| Chu Poitiers - Poitiers 2986495 - France | Contact (sur clinicalTrials) | ||||
| Chu Toulouse - Toulouse 2972315 - France | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Ap-Hp Tenon - Paris 2988507 - France | Contact (sur clinicalTrials) | ||||
| Centre François Baclesse - Caen 3029241 - France | Contact (sur clinicalTrials) | ||||
| Institut Gustave Roussy IGR - Villejuif 2968705 - France | Contact (sur clinicalTrials) | ||||
Critères
Femme
- 18 year old woman or over at the time of participation
- PS 0 -2
- Cancer diagnosed (biopsy date) from 01/01/2010 between the second week of pregnancy
and the 12 months postpartum.
- Primitive may concern the following sites:
oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, prevalent lymphadenopathy,
nasal cavity, salivary glands, dental tumors, ear tumors, paragangliomas optic pathways,
facial sinus / facial mass, nose, ear and other head and neck
- All histologies (epithelial tumors, sarcomas, mucosal melanomas, embryonic tumors,
undifferentiated tumors)
- Patient receiving or having received a specific oncological treatment among surgery,
radiotherapy, chemotherapy, hormone therapy.
- All stages allowed: localized stages and metastatic stages immediately.
- No opposition of the patient to participate in this study
Exclusion Criteria:
- Any other neoplastic antecedent
- Exclusion of metastases at the level of the VADS of another primitive than a cancer
of the VADS
- Exclusion of hematological tumors (lymphoma) and glial tumors
- Person subject to a legal protection measure or unable to express their consent